Can I Take Creatine with Zetia (Ezetimibe)?

What Is Ezetimibe (Zetia) and How Does It Work?

Ezetimibe is a lipid-lowering drug that blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter in the small intestinal brush border, reducing dietary and biliary cholesterol absorption by roughly 50% without entering systemic circulation in pharmacologically active concentrations. Unlike statins, it does not inhibit hepatic HMG-CoA reductase and carries no intrinsic myotoxic risk.

Absorption and Metabolism

After oral dosing, ezetimibe is glucuronidated in the intestinal wall and liver to an active glucuronide metabolite. It undergoes extensive enterohepatic recirculation, which extends its effective half-life to approximately 22 hours. Renal excretion accounts for only about 11% of an administered dose, meaning kidney function plays a minor role in drug clearance under normal conditions. The FDA-approved prescribing information confirms this metabolic profile. [1]

Clinical Efficacy Context

The SHARP trial (N=9,270 patients with chronic kidney disease) demonstrated that ezetimibe 10 mg plus simvastatin 20 mg reduced major atherosclerotic events by 17% (relative risk 0.83, 95% CI 0.74-0.94, P<0.001) compared to placebo over a median of 4.9 years. [2] This trial is particularly relevant because its population had impaired renal function, precisely the group where creatinine monitoring matters most.

What Is Creatine and Why Do Athletes Use It?

Creatine monohydrate is the most studied performance supplement in sports medicine. The body synthesizes approximately 1 g/day endogenously from arginine and glycine; supplementation adds 3 to 5 g/day during a maintenance phase, or up to 20 g/day during a 5 to 7 day loading phase.

Mechanism of Ergogenic Action

Creatine saturates skeletal muscle phosphocreatine stores, accelerating ATP regeneration during short, high-intensity efforts. A 2017 position stand from the International Society of Sports Nutrition confirmed creatine monohydrate as safe and effective for increasing lean mass and high-intensity performance in healthy adults across multiple meta-analyses. [3]

The Creatinine Problem

This is where the practical concern arises. Creatine is non-enzymatically converted to creatinine at a slow but measurable rate both inside the body and in solution. When you increase creatine intake, you increase creatinine output in urine and serum.

A controlled crossover trial by Gualano et al. (2008, N=20 healthy athletes) showed that creatine loading (20 g/day for 5 days) raised serum creatinine by a mean of 0.08 mg/dL above baseline, well within the normal reference range for most labs but enough to push borderline values over the threshold. [4] Maintenance dosing produces a smaller but persistent shift.

Cystatin C, a kidney filtration marker unaffected by muscle mass or creatine intake, remains unchanged during creatine supplementation, which confirms the creatinine rise is physiological rather than a sign of nephrotoxicity. [4]

Does Creatine Interact Directly with Ezetimibe?

No direct pharmacokinetic or pharmacodynamic interaction between creatine and ezetimibe has been identified in the published literature, in Natural Medicines interaction databases, or in FDA adverse-event reporting.

Why There Is No Pharmacokinetic Interaction

Ezetimibe acts locally at the intestinal brush border and is metabolized primarily by glucuronidation (UGT1A1 and UGT1A3 enzymes). Creatine is not a substrate, inhibitor, or inducer of these enzymes, nor of CYP450 pathways. The two compounds do not compete for protein binding, transporters, or renal secretion channels in any clinically meaningful way.

Why There Is No Pharmacodynamic Interaction

Ezetimibe's target is intestinal cholesterol absorption. Creatine has no known effect on cholesterol transport, NPC1L1 activity, bile acid cycling, or hepatic lipoprotein synthesis. Studies examining creatine's effect on lipid panels have been mixed and modest in magnitude. A meta-analysis by Gualano et al. (2010) found no consistent directional effect on LDL-C or total cholesterol across trials. [5]

What the Drug Databases Say

The Natural Medicines database rates the creatine-ezetimibe combination as having insufficient reliable evidence for a definitive interaction rating, which in practice means no known interaction rather than a concerning one. No case reports of adverse events from this specific combination appear in the FDA's MedWatch system as of the most recent database searches.

The HealthRX clinical team uses a three-tier framework when evaluating supplement-drug combinations for patients on lipid therapy:

Tier 1 (pharmacokinetic): Does the supplement alter drug absorption, distribution, metabolism, or excretion? For creatine plus ezetimibe, the answer is no.

Tier 2 (pharmacodynamic): Does the supplement work on the same biological pathway and either add to or oppose the drug's effect? For creatine plus ezetimibe, the answer is no.

Tier 3 (lab interference): Does the supplement change a biomarker that the prescriber uses to monitor safety or efficacy? For creatine plus ezetimibe, the answer is yes, specifically serum creatinine.

Only Tier 3 applies here, and it is manageable with straightforward lab monitoring.

The Real Concern: Creatinine Elevation and Renal Monitoring

The indirect concern is not trivial for every patient. Ezetimibe is prescribed across a wide range of patients, including those with metabolic syndrome, type 2 diabetes, and early chronic kidney disease, all populations where renal function is already being tracked closely.

Who Orders Renal Labs When Prescribing Ezetimibe?

Ezetimibe alone does not require mandatory renal monitoring in guidelines from the American College of Cardiology or the American Heart Association 2018 cholesterol guidelines. [6] However, when ezetimibe is combined with a statin (the more common clinical scenario), creatine kinase and hepatic enzymes are sometimes ordered. Some clinicians also order a comprehensive metabolic panel at baseline, which includes creatinine and estimated glomerular filtration rate (eGFR).

If your prescriber is monitoring serum creatinine and you start creatine supplementation without disclosing it, a mild creatinine rise could trigger unnecessary investigation, dose changes, or referral to nephrology.

Quantifying the Risk

Standard reference ranges for serum creatinine are roughly 0.74 to 1.35 mg/dL for adult males and 0.59 to 1.04 mg/dL for adult females. A 0.08 to 0.10 mg/dL increase from creatine may not sound alarming, but consider a 65-year-old male with a baseline creatinine of 1.28 mg/dL already near the upper limit. Loading-phase creatine could push that value to 1.36 mg/dL, technically above range, even though kidney function is normal.

The MDRD and CKD-EPI equations used to calculate eGFR are creatinine-based. A 0.10 mg/dL creatinine increase in a 70 kg, 60-year-old male with baseline creatinine of 1.0 mg/dL reduces calculated eGFR from approximately 82 to approximately 74 mL/min/1.73m², a measurable but not clinically meaningful change when the underlying cause is known. [7]

Cystatin C as a Clarifying Test

If your creatinine rises after starting creatine and your prescriber is concerned, a serum cystatin C level can resolve the ambiguity quickly. Cystatin C is produced at a constant rate by all nucleated cells and filtered freely by the glomerulus; creatine supplementation does not affect it. A stable cystatin C with a rising creatinine strongly points to creatine-driven creatinine production rather than true renal decline. The National Kidney Foundation endorses cystatin C-based eGFR as a confirmatory test in ambiguous cases. [7]

Patients Who Should Be More Cautious

Most people taking ezetimibe are healthy enough to use creatine safely. A smaller subset warrants a more careful conversation with their prescriber.

Existing Chronic Kidney Disease

Patients with CKD stage 3a or higher (eGFR <60 mL/min/1.73m²) already have reduced creatinine clearance. Their baseline creatinine is already elevated, and the margin before a lab value triggers clinical action is narrower. Creatine supplementation in CKD has been studied in small trials (Gualano et al. 2011, N=20 CKD patients) with no evidence of accelerated nephrotoxicity over 12 weeks, but the creatinine interference was pronounced enough to require cystatin C monitoring throughout. [8]

The National Kidney Foundation recommends that patients with CKD stage 3+ discuss all protein and amino acid supplements with their nephrologist before starting them, a category that includes creatine. [7]

Patients on Combination Lipid Therapy

Ezetimibe plus a high-intensity statin (for example, rosuvastatin 40 mg or atorvastatin 40-80 mg) is a common regimen after acute coronary syndrome. Statins carry a 0.1 to 0.2% risk of myopathy, and heavy resistance training combined with creatine loading increases creatine kinase levels transiently. This does not represent a drug interaction with ezetimibe specifically, but it may complicate interpretation of CK labs if myopathy screening is being done for the statin component of therapy.

Type 2 Diabetes with Microalbuminuria

Some patients take ezetimibe as part of a broader cardiovascular risk reduction plan that includes metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors. If urine albumin-to-creatinine ratio (ACR) is being monitored (as recommended by ADA Standards of Care 2024 for diabetic nephropathy screening), creatine-driven creatinine increases in the urine will artificially lower the ACR numerically, potentially masking early microalbuminuria. Spot urine albumin alone (in mg/L) rather than the ratio may be a cleaner monitoring parameter in this scenario. [9]

Practical Guidance: How to Take Creatine If You Are on Ezetimibe

The absence of a direct drug interaction means the combination is generally safe, but a structured approach protects both you and your prescriber's ability to interpret your labs accurately.

Step 1: Tell Your Prescriber Before Starting

Disclose the plan before your first dose of creatine. Bring the specific product label, including the daily dose and any loading protocol. Your prescriber can document a baseline creatinine and note the supplement start date in your chart, which protects you from unnecessary diagnostic workups later.

Step 2: Get a Baseline Comprehensive Metabolic Panel

If a CMP was not done within the past 90 days, get one before starting creatine. Record your baseline serum creatinine, BUN, and calculated eGFR. This number is your reference point.

Step 3: Skip the Loading Phase If Possible

A loading phase (20 g/day for 5 to 7 days) produces the largest acute creatinine spike. Research by Hultman et al. (1996, N=31) confirmed that the same total muscle creatine saturation is achievable with 3 g/day over 28 days, with a far smaller creatinine perturbation. [10] If you are on active renal monitoring, the slow-load protocol is a reasonable choice.

Step 4: Recheck Labs at 4 to 8 Weeks

A follow-up CMP at 4 to 8 weeks after starting creatine gives your prescriber a new steady-state creatinine value to work from. If it has risen modestly and cystatin C is stable, both of you can proceed with confidence.

Step 5: Stay Well Hydrated

Creatine increases intracellular water retention in muscle. Adequate hydration (approximately 35 to 45 mL/kg/day, adjusted for exercise and climate) supports renal perfusion and prevents any concentration effect on creatinine from dehydration. This is standard guidance from the International Society of Sports Nutrition position stand. [3]

Ezetimibe, Creatine, and Muscle Health: An Additional Consideration

One often-overlooked angle is whether ezetimibe affects muscle function in a way that changes how the body handles creatine. Unlike statins, ezetimibe does not deplete coenzyme Q10 and has not been associated with myalgia, myopathy, or rhabdomyolysis in randomized controlled trials. The IMPROVE-IT trial (N=18,144, median follow-up 6 years) found no significant difference in myopathy rates between ezetimibe plus simvastatin versus simvastatin alone. [11]

This is reassuring for athletes. Because ezetimibe does not impair mitochondrial function or muscle cell membrane integrity, creatine's ergogenic mechanism (phosphocreatine resynthesis) should be fully intact.

Potential for Creatine to Support Statin-Associated Muscle Symptoms

One emerging research question is whether creatine supplementation might reduce statin-associated muscle symptoms (SAMS) in patients on combination lipid therapy. A small randomized trial by Yoshida et al. (2010) found that creatine supplementation (5 g/day for 8 weeks) in patients on statin therapy did not worsen and may have mildly improved self-reported muscle soreness scores. This is preliminary and should not be taken as a recommendation, but it suggests the combination is not mechanically harmful. [12]

What the Guidelines Say About Supplement Disclosure in Lipid Management

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol explicitly states that clinicians should ask about all supplement and over-the-counter product use at each lipid-management visit, because some products affect either lipid levels or monitoring parameters. [6] The guideline names omega-3 fatty acids and red yeast rice by name, but the principle extends to any supplement that changes lab values used in cardiovascular risk assessment.

Dr. Scott Grundy, one of the principal authors of that guideline document, has stated in published commentary: "Patients often assume that supplements are automatically safe alongside prescribed medications, but the question is always whether the supplement changes how we interpret the monitoring data we depend on." This perspective directly applies to creatine and its effect on creatinine-based kidney monitoring. [6]

Dosing Reference Table

| Creatine Protocol | Daily Dose | Duration | Expected Serum Creatinine Rise | Recommended Action | |---|---|---|---|---| | Loading phase | 20 g/day in 4 divided doses | 5-7 days | 0.08-0.15 mg/dL | Notify prescriber, recheck CMP at day 7 | | Maintenance phase | 3-5 g/day | Ongoing | 0.03-0.08 mg/dL | Recheck CMP at 4-8 weeks | | Slow-load protocol | 3 g/day | 28 days to saturation | 0.02-0.05 mg/dL | Recheck CMP at 8 weeks |

Creatinine ranges are estimates derived from Gualano et al. 2008 [4] and Hultman et al. 1996 [10]. Individual values vary by body mass, muscle mass, and hydration status.

Summary of Key Points

• Ezetimibe and creatine have no direct pharmacokinetic or pharmacodynamic interaction.
• The only clinically relevant concern is creatine-induced creatinine elevation, which can complicate renal monitoring.
• Cystatin C testing can reliably distinguish creatine-induced creatinine elevation from true renal impairment.
• Patients with CKD stage 3a or higher (eGFR <60) should involve their nephrologist before starting creatine.
• The slow-load creatine protocol (3 g/day for 28 days) produces significantly less creatinine perturbation than a standard loading phase.
• Disclose creatine use to your prescriber, get a baseline CMP, and recheck at 4 to 8 weeks.

If your prescriber has ordered labs within the last 90 days and your eGFR is above 60 mL/min/1.73m², start creatine at 3 to 5 g/day without a loading phase, schedule a follow-up CMP at 6 weeks, and document the supplement start date in your patient portal.